- Home
- VBNK vs CSTL Comparison
VBNK vs CSTL Comparison
Compare VBNK & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBNK
- CSTL
- Stock Information
- Founded
- VBNK 1980
- CSTL 2007
- Country
- VBNK Canada
- CSTL United States
- Employees
- VBNK N/A
- CSTL N/A
- Industry
- VBNK Commercial Banks
- CSTL Medical Specialities
- Sector
- VBNK Finance
- CSTL Health Care
- Exchange
- VBNK Nasdaq
- CSTL Nasdaq
- Market Cap
- VBNK 441.5M
- CSTL 456.2M
- IPO Year
- VBNK 2021
- CSTL 2019
- Fundamental
- Price
- VBNK $11.29
- CSTL $15.91
- Analyst Decision
- VBNK Strong Buy
- CSTL Strong Buy
- Analyst Count
- VBNK 3
- CSTL 6
- Target Price
- VBNK $19.00
- CSTL $37.67
- AVG Volume (30 Days)
- VBNK 27.3K
- CSTL 527.3K
- Earning Date
- VBNK 06-04-2025
- CSTL 05-05-2025
- Dividend Yield
- VBNK 0.62%
- CSTL N/A
- EPS Growth
- VBNK N/A
- CSTL N/A
- EPS
- VBNK 0.89
- CSTL N/A
- Revenue
- VBNK $75,813,751.00
- CSTL $347,083,000.00
- Revenue This Year
- VBNK $12.97
- CSTL N/A
- Revenue Next Year
- VBNK $43.72
- CSTL $1.80
- P/E Ratio
- VBNK $15.69
- CSTL N/A
- Revenue Growth
- VBNK N/A
- CSTL 38.43
- 52 Week Low
- VBNK $8.51
- CSTL $15.45
- 52 Week High
- VBNK $18.38
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- VBNK 49.85
- CSTL 34.64
- Support Level
- VBNK $11.17
- CSTL $15.62
- Resistance Level
- VBNK $12.00
- CSTL $16.43
- Average True Range (ATR)
- VBNK 0.33
- CSTL 0.57
- MACD
- VBNK -0.02
- CSTL 0.07
- Stochastic Oscillator
- VBNK 26.81
- CSTL 24.77
About VBNK VersaBank
VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.